This category focuses on techniques that adapt non-human antibodies for clinical applications. It discusses frameworks for reducing immunogenicity, enhancing compatibility, and retaining antibody function.
Since the first recombinant protein therapeutic, human insulin, was approved in 1982, more than 250 protein-based drugs have entered the global market. Monoclonal antibodies (mAbs), in particular, are a rapidly growing class of biologics, representing nearly half of all therapeutic proteins approved by the U.S. Food and Drug Administration (FDA) in recent years.
Humanization enhances antibody safety and efficacy. Biointron reviews CDR grafting and advanced techniques transforming antibody development.
Antibody humanization reduces immunogenicity and preserves specificity. Biointron highlights methods that transform murine antibodies into safe, effective therapies.
Learn how antibody humanization reduces immunogenicity in therapies. Explore CDR grafting, phage display, and Biointron’s rapid humanization services.
You can also contact us on the Scientist and Science Exchange marketplaces.
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.
